Core Insights - A drug named "Suxamethonium," a carbonic anhydrase inhibitor, significantly reduces apnea episodes in patients with obstructive sleep apnea, improving sleep quality [1] - The clinical study involved 298 moderate to severe obstructive sleep apnea patients across four European countries, with a double-blind design [1][2] - High-dose Suxamethonium reduced apnea events by up to 47% compared to placebo, with notable improvements in blood oxygen levels [1] Group 1 - Obstructive sleep apnea is a common sleep disorder that can lead to serious health risks if untreated, including hypertension, cardiovascular diseases, stroke, and type 2 diabetes [1] - Continuous positive airway pressure (CPAP) is the primary treatment, but many patients struggle to adhere to it, with up to 50% abandoning treatment within a year due to discomfort [2] - Suxamethonium is already approved for treating pediatric epilepsy, and researchers have explored its potential for treating sleep apnea [2]